16 results about "Coronary atherosclerosis" patented technology

The invention discloses a circular non-coding RNA (Ribonucleic Acid) molecule circSENP6 and application thereof. The nucleotide sequence of the circSENP6 is shown as SEQ ID NO. 1. The invention also discloses a preparation method of the circular non-coding RNA molecule circSENP6. The circular non-coding RNA molecule circSENP6 can be used as a diagnostic biomarker for coronary atherosclerosis, is used for biological identification and clinical detection of coronary atherosclerotic heart disease, and can be used for early discovering coronary heart disease patients, reducing the death rate of coronary heart disease and improving the prognosis of patients by using the expression level of the gene for diagnosis. At present, the main diagnosis method for coronary atherosclerotic heart disease has the risks of high operation danger coefficient, large radiation and the like, and by collecting peripheral blood of a patient for detection, the method has the advantages of small trauma, good repeatability and the like, and is easier to accept.

The invention discloses a circular non-coding RNA molecule hascirc0000799, which can be used as a diagnostic biomarker for coronary atherosclerosis, is used for biological identification and clinical detection of coronary atherosclerotic heart disease, and can find coronary heart disease patients at an early stage, reduce the death rate of the coronary heart disease and improve the prognosis of the patients by using the expression level of the gene for diagnosis. At present, the main diagnosis method for coronary atherosclerotic heart disease has the risks of high operation danger coefficient, large radiation and the like, and by collecting peripheral blood of a patient for detection, the method has the advantages of small trauma, good repeatability and the like, and is easier to accept.

The present application discloses the application of coelenterazine or its salt in the preparation of a medicament for treating or preventing myocardial infarction, preferably myocardial infarction caused by insufficient blood supply, myocardial hypoxia and myocardial excessive oxygen consumption due to various causes such as coronary atherosclerosis, arrhythmia, respiratory failure, but not limited to the above inducers. Specifically, the medicament can inhibit or improve various myocardial infarction.

The present invention discloses a method, system and medium for constructing a data grading model of coronary atherosclerotic heart disease, belonging to the technical field of data analysis. The present invention includes: obtaining the diagnostic records of patients and calculating the comprehensive characteristic values of the diagnostic records; classifying and counting the diagnostic records of all patients, calculating the characteristic thresholds of each type of diagnostic records, and constructing a sclerosis grade model; calculating the characteristic change amount of patients and matching the target patients; obtaining the treatment records of the target patients, generating suggestion information, and improving the sclerosis grade model; according to the real-time diagnostic records of patients and the sclerosis grade model, outputting the sclerosis grade of patients and suggestion information; the present invention can not only make a more accurate and comprehensive assessment according to the diagnostic records of patients, but also recommend appropriate treatment plans for early patients, timely adjust medical intervention measures, and comprehensively improve the diagnosis and treatment effect and the patient health management level.

The invention relates to a traditional Chinese medicine composition for treating cardiovascular and cerebrovascular diseases, and belongs to the technical field of treatment of cardiovascular and cerebrovascular diseases. The traditional Chinese medicine composition for treating cardiovascular and cerebrovascular diseases takes yang warming and body resistance strengthening as a core, is added with insect medicines for dredging collaterals and is combined with traditional Chinese medicines for promoting blood circulation to remove blood stasis; a traditional Chinese medicine composition mainly comprising pilose antler, wild ginseng under forest, centipede, Yunnan poecilobdella manillensis and the like is created and prepared into water-honeyed pills to be taken; after clinical application, the water-honeyed pills have obvious curative effects on patients suffering from coronary atherosclerotic cardiovascular and cerebrovascular diseases, including patients with poor western medicine treatment effects, and meanwhile, high-risk factors such as hypertension, hyperglycemia and hyperlipidemia of the patients are effectively corrected; the traditional Chinese medicine composition is used for treating metabolic syndrome, systemic atherosclerosis, deficiency arrhythmia and cardiovascular and cerebrovascular diseases in the early stage and the recovery stage, and the symptoms of the cardiovascular and cerebrovascular diseases can be improved after the traditional Chinese medicine composition is taken for at least three weeks.

The present invention discloses a drug-loading system with the ability of targeted drug delivery within coronary atherosclerotic plaques and a preparation method thereof. Using PBCA NPs synthesized from BCA monomers under the suspension aggregation and protocol as a drug carrier, when used in conjunction with intravascular ultrasound (IVUS), targeted drug delivery can be achieved, namely, the IVUS-PBCA NPs targeted drug delivery system. The PBCA NPs drug carrier prepared by the present invention has an average particle size of 216 nm, a stable negative potential of -22.2 mV on the surface, is safe and non-toxic, can match the high-frequency probe of IVUS, and has an ultrasound enhancement effect, thereby improving the resolution of IVUS. Moreover, under the action of the IVUS ultrasonic radiation force, it can penetrate through the gaps of the diseased vascular endothelium to reach the inside of the lesion, and then naturally hydrolyze, releasing the internal drug to achieve targeted drug delivery.

The invention belongs to the technical field of biology, and relates to a circular RNA (Ribonucleic Acid) marker for diagnosing coronary atherosclerotic heart disease, a kit and application of the circular RNA marker. The expression level of the circular RNA hsacirc0003141 disclosed by the invention is obviously up-regulated in blood of a research object of the coronary atherosclerotic heart disease, which indicates that the circular RNA hsacirc0003141 has the potential of becoming a biomarker of the coronary atherosclerotic heart disease.

This invention belongs to the field of biomedicine and discloses the use of NLRC3 in the preparation of products for diagnosing, screening, or evaluating coronary atherosclerotic heart disease. It provides a novel marker, NLRC3, for detecting coronary heart disease. The marker exhibits excellent stability, making it convenient and less invasive for the diagnosis of coronary heart disease while avoiding radiation risks. NLRC3 expression is significantly downregulated in human carotid artery plaques compared with normal carotid arteries; NLRC3 expression in peripheral blood mononuclear cells of patients with coronary heart disease is significantly lower than that in patients with normal coronary arteries; and NLRC3 expression in the plasma of patients with coronary heart disease is significantly lower than that in patients with normal coronary arteries. The receiver operating characteristic (ROC) curve analysis showed an AUC value as high as 0.926. When the diagnostic threshold for NLRC3 relative expression was set at 0.012, the sensitivity reached 85% and the specificity reached 80%. The accuracy of screening for coronary heart disease in patients with chest pain was 84.4%, demonstrating excellent clinical application value.

The present application relates to a kind of traditional Chinese medicine composition for treating coronary atherosclerotic disease stable angina, the traditional Chinese medicine composition is made of the following weight parts of raw medicinal materials: Radix Bupleuri 10-14 parts, Ramulus Cinnamomi 3-7 parts, Herba Agrimoniae 13-17 parts, Salvia Miltiorrhiza 13-17 parts, Radix Paeoniae Alba 3-7 parts, Rhizoma Pinelliae Praeparatum 4-8 parts, Radix Scophularae 3-7 parts, Radix Ginseng 3-7 parts, Radix Glycyrrhizae 1-5 parts, Zingiber officinale 3-7 parts, Fructus Jujubae 4-8 parts.The present application also provides the application of traditional Chinese medicine composition in the preparation of medicine for treating coronary atherosclerotic disease stable angina.The treatment principle of the present application is: regulating liver and unblocking yang, regulating qi and activating blood.The drugs in the present application are used together, and the effect is enhanced, can regulate Ying and Wei, regulate liver qi, unblock chest yang, and unblock blood vessels, so as to achieve the effect of preventing and treating stable angina pectoris of coronary heart disease.The present application can effectively improve the angina pectoris symptoms of patients with stable angina pectoris of coronary heart disease, improve the quality of life of patients, has certain clinical value, and is worth further research and promotion.

This invention belongs to the interdisciplinary field of bioinformatics and traditional Chinese medicine (TCM), and discloses an algorithm for the improvement and prediction of TCM compound prescriptions, solving the problems of strong subjectivity, long cycle, and low efficiency in traditional TCM compound prescription improvement. The algorithm first acquires and preprocesses omics sequencing data from disease and healthy groups, then establishes TCM-target gene associations based on the HIT2 and TCMSP databases, and constructs a three-dimensional association matrix of TCM-target genes-5hmC loci for epigenomic data. After dimensionality reduction and extraction of core principal components using PCA, the sample-TCM association score is calculated and a matrix is ​​constructed. The p-value is obtained through t-test or Wilcoxon rank-sum test, and converted into DAS values ​​to quantify the regulatory activity of TCM, thus screening TCM for compound prescription improvement. This invention's algorithm is objective, highly targeted, efficient, and widely applicable, adaptable to various omics data and disease scenarios. Its effectiveness has been verified in a coronary atherosclerosis case, providing precise technical support for TCM compound prescription screening and optimization, personalized TCM treatment, and the development of innovative TCM drugs.

The invention relates to the technical field of biological medicine, in particular to a biological marker for coronary atherosclerosis bifurcation lesion and application of the biological marker. The invention discloses application of PlexinD1 as a marker in preparation of a product for treating, preventing or diagnosing bifurcation lesion. The product comprises a reagent or a kit. Compared with imaging examination means such as coronary CTA, coronary angiography, OCT, IVUS, molecular imaging and the like, the bifurcation lesion can be recognized more economically, conveniently and quickly, no special requirement for diagnostic equipment and reagents is needed, and batch measurement of samples can be achieved only through a single ELISA kit.

The present invention discloses a traditional Chinese medicine preparation for treating coronary atherosclerotic heart disease complicated with anxiety and depression. The preparation is prepared from the following raw materials: 25-35 g of processed Chuanwu, 8-12 g of black aconite root, 25-35 g of cinnamon twig, 25-35 g of bupleurum root, 25-35 g of turmeric root, 25-35 g of cyperus rotundus, 25-35 g of immature bitter orange, 25-35 g of atractylodes macrocephala, 45-55 g of raw dragon bone, 45-55 g of raw oyster, 25-35 g of raw betel nut, 25-35 g of toosendan fruit, and 25-35 g of green tangerine peel. Clinical studies have shown that the traditional Chinese medicine preparation of the present invention significantly improves symptoms such as chest tightness and pain, palpitations, shortness of breath, insomnia, anxiety, irritability, and depression in patients after treatment, compared with a control group (taking delexin orally). The improvement in SAQ scores, HAMD scores, HAMA scores, and TCM syndrome scores is also better than that of the control group, demonstrating significant efficacy.

The present application provides a traditional Chinese medicine composition for treating and / or preventing coronary heart disease, and a preparation method and application thereof. Specifically, the traditional Chinese medicine composition of the present application is prepared from raw materials comprising the following components: 8-13 parts of capillaris, 8-12 parts of atractylodes, 8-12 parts of alisma, 8-14 parts of curcuma, 10-20 parts of salvia, 8-14 parts of curcuma, 1-5 parts of panax notoginseng powder, 5-10 parts of rhizoma corydalis, 8-12 parts of pinellia, 5-10 parts of berberis, 4-10 parts of ginseng, 5-12 parts of dried tangerine or orange peel, and 4-10 parts of licorice. The present application also provides a method for preparing the traditional Chinese medicine composition of the present application and the use of the traditional Chinese medicine composition in preparing a medicine for treating and / or preventing coronary atherosclerotic heart disease. The traditional Chinese medicine composition of the present application can reduce blood viscosity, improve heart function, reduce myocardial infarction area, inhibit the formation of atherosclerotic plaques, regulate blood lipid levels, or reduce the level of myocardial injury markers in serum.

The scheme discloses a drug for treating coronary atherosclerotic ischemic heart disease in the field of cardiovascular disease related drugs and application, and comprises Faban 5-10g, Zhuyu 5-10g, Zhishi 5-10g, Chenpi 10-15g, Fuling 5-10g, Shengjiang 5-10g, Gancao 5-10g, Danshen 10-15g, Tuobiechong 5-10g, Huanglian 3-5g and Guizhi 5-10g. The curative effects of the drugs in the compound prescription produce a synergistic effect, can effectively prevent and treat the recurrence of coronary atherosclerotic ischemic heart disease, and especially have a good treatment effect on coronary heart disease with phlegm and blood stasis.

The invention provides a traditional Chinese medicine composition for treating and / or preventing coronary heart disease as well as a preparation method and application thereof. Specifically, the traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 8-13 parts of herba artemisiae scopariae, 8-12 parts of rhizoma atractylodis, 8-12 parts of rhizoma alismatis, 8-14 parts of rhizoma curcumae longae, 10-20 parts of radix salviae miltiorrhizae, 8-14 parts of radix curcumae, 1-5 parts of pseudo-ginseng powder, 5-10 parts of rhizoma corydalis, 8-12 parts of pinellia ternate, 5-10 parts of coptis chinensis, 4-10 parts of ginseng, 5-12 parts of pericarpium citri reticulatae and 4-10 parts of liquorice. The invention also provides a method for preparing the traditional Chinese medicine composition and application of the traditional Chinese medicine composition in preparation of medicines for treating and / or preventing coronary atherosclerotic heart disease. The traditional Chinese medicine composition can reduce the blood viscosity, improve the heart function, reduce the myocardial infarction area, inhibit atherosclerotic plaque formation, regulate the blood fat level or reduce the myocardial injury marker level in serum.

The application relates to a Polar-TransUnet network-based intravascular ultrasound image boundary extraction method, which comprises the following steps: data enhancement; obtaining an IVUS image classification result; and extracting an IVUS image boundary.The application has the beneficial effects that: by customizing data enhancement and building a TransUnet network, the application obtains a pixel-level classification result of an IVUS image, realizes accurate boundary extraction of the IVUS image, has important significance for the diagnosis of clinical coronary atherosclerosis, and also has reference significance for the processing of other annularly distributed medical images.